In April, the FDA announced an ambitious plan to phase out animal testing requirements for monoclonal antibodies and other therapies in an effort to improve drug safety and reduce R&D costs. The goal ...

Infinimmune sees the human body as a kind of prototyping platform for antibody medicines, one that holds considerable advantages over model organisms, display libraries, or computational algorithms.

Antibodies are essential for immune defense and safeguarding against bacteria, viruses, and other foreign entities. Produced by B cells, these protein molecules offer the potential for treating ...